Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window of Opportunity Clinical Trial

PURPOSE: Ras/MEK/ERK pathway activation is common in oral cavity squamous cell carcinoma (OCSCC). We performed a neoadjuvant (pre-operative) trial to determine biomarker and tumor response of OCSCC to MEK inhibition with trametinib. PATIENTS AND METHODS: Patients with Stage II–IV OCSCC received tram...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Cancer Res
Prif Awduron: Uppaluri, Ravindra, Winkler, Ashley E., Lin, Tianxiang, Law, Jonathan H., Haughey, Bruce H., Nussenbaum, Brian, Paniello, Randal C., Rich, Jason T., Diaz, Jason A., Michel, Loren P., Wildes, Tanya M., Dunn, Gavin P., Zolkind, Paul, Kallogjeri, Dorina, Piccirillo, Jay F., Dehdashti, Farrokh, Siegel, Barry A., Chernock, Rebecca D., Lewis, James S., Adkins, Douglas R.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2016
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5509449/
https://ncbi.nlm.nih.gov/pubmed/28151720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1469
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg